ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Nose to brain delivery of dapoxetine-loaded PLGA nanoparticle for treatment of premature ejaculation distress in normal and diabetic rats with in silico targeting brain FOX and serotonin proteins.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electrostatic-tailored Leciplex system of ketoconazole for boosted ocular pharmacology and cytotoxicity assessment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychological and emotional sexual conditions in men include premature ejaculation. Premature Ejaculation (PE) has 4%-66% worldwide effects on self-esteem, relationships, and quality of life. Poor sexual confidence, anxiety, and sadness may worsen the issue. For this disease, dapoxetine HCl (DH) is used. In normal and streptozotocin (STZ)-induced diabetic rats, DH-loaded poly (lactic-co-glycolic acid) PLGA NP intranasal (IN) therapy was compared to standard lidocaine for DH release, entrapment efficiency, behavioural analysis, histopathological and immunohistochemistry expression, as neuroprotection inspection and proto-oncogene c-Fos (FOS) protein sequence expression. Also, in silico brain serotonin and FOS protein analyses were performed. Double-emulsion-solvent evaporation produced DH-loaded PLGA NP for IN quick-acting PE. Safe, controlled release, and effectiveness were investigated in PE rats using DH-PLGA NP. The brain's FOS protein expression, mount, intromission, post-ejaculatory, and Ejaculation frequencies were estimated. Optimized spherical NPs were 174 nm in size, - 69.45 mV zeta potential, 98.04% entrapment efficiency, and 78.61% release after 8 h. The brain's ejaculation centre's rapid-acting DH prolongs intra-ejaculation, lowers FOS protein density, and normalizes hippocampus neurons. Histology and immunohistochemistry confirmed behavioural results of lower FOS protein expression and delayed ejaculation. Docking revealed that the DH ligand binds more strongly to brain protein active sites involved in premature ejaculation via rapid brain delivery bypassing the BBB via IN dosing, confirmed by behavioural analysis, histopathology, and immunohistochemistry. Using DH acutely decreased rapid ejaculation and changed contextual neuronal activity in ejaculatory network brain regions. Our results improve PE neurobiology and pharmacology research. Expression of FOS protein in DH nanoformula IN protects normal and diabetic rats in normal and diabetic premature ejaculated rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.